Soligenix (NASDAQ: SNGX) and SIGA Technologies (OTCMKTS:SIGA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.
Risk and Volatility
Soligenix has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.
Earnings and Valuation
This table compares Soligenix and SIGA Technologies’ revenue, earnings per share and valuation.
||Earnings Per Share
Soligenix has higher earnings, but lower revenue than SIGA Technologies. SIGA Technologies is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.
This table compares Soligenix and SIGA Technologies’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Institutional & Insider Ownership
1.7% of Soligenix shares are held by institutional investors. Comparatively, 6.7% of SIGA Technologies shares are held by institutional investors. 5.0% of Soligenix shares are held by insiders. Comparatively, 4.7% of SIGA Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a breakdown of recent recommendations for Soligenix and SIGA Technologies, as provided by MarketBeat.
||Strong Buy Ratings
Soligenix presently has a consensus target price of $5.25, indicating a potential upside of 141.94%. Given Soligenix’s higher possible upside, equities research analysts clearly believe Soligenix is more favorable than SIGA Technologies.
Soligenix beats SIGA Technologies on 7 of the 13 factors compared between the two stocks.
Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.
About SIGA Technologies
SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.